Research Only Cognitive & Nootropic

BRN2 (POU3F2) Research Peptide

also known as: POU3F2-derived peptide, N-Oct3 fragment

A research-only peptide derived from the POU3F2 (BRN2) neural transcription factor; mechanistic and phenotypic evidence is limited almost entirely to in vitro and lineage-specification studies. No human therapeutic development, no clinical trials, no established dosing, and no commercial availability through regulated channels.

A short peptide fragment corresponding to a sequence within the POU-domain transcription factor BRN2 (encoded by POU3F2, also called N-Oct3). BRN2 is required for specification and differentiation of cortical upper-layer neurons and of melanocyte progenitors. The peptide has appeared sporadically in preclinical transcription-factor mimetic literature and in nootropic-adjacent grey-market catalogs. There is no coherent clinical development program, no human pharmacokinetic or safety data, and no substantiated therapeutic claim.

Mechanism of action

BRN2 is a class III POU-domain transcription factor required for the specification of upper-layer cortical neurons and of the melanocyte lineage. Short peptides derived from the BRN2 sequence have been studied as tools for probing transcription factor function or as putative cell-penetrating fragments. No coherent cellular or in vivo mechanism of action as a therapeutic peptide has been established.

Primary uses

Transcription-factor research (in vitro)
Neuronal differentiation studies (in vitro)

Typical dosing

Not established

⚠ No human dosing has ever been established. Any human use would be entirely experimental and unsupported by preclinical safety or efficacy data.

Regulatory status

Not FDA-approved. Not in any registered clinical trial. No therapeutic sponsor. Circulates in grey-market nootropic listings with unverified provenance and purity; any human use would be entirely unregulated and unsupported.

References

[pubmed] McEvilly RJ, et al. "Transcriptional regulation of cortical neuron migration by POU domain factors." Science, 2002;295:1528-1532 (BRN2 developmental biology).
[pubmed] Cook AL, et al. "The role of BRN2 in melanocytes and melanoma." Pigment Cell Melanoma Res, 2008;21:611-626 (BRN2 lineage biology).

Related peptides

NPAS3 Research Peptide

A research-only peptide derived from the NPAS3 (neuronal PAS domain protein 3) basic helix-loop-helix PAS transcription factor. NPAS3 has been linked to schizophrenia and cognitive phenotypes in human genetic studies, but the peptide itself has no clinical development. No human trials, no established dosing, and no substantiated therapeutic use.

P21

A CNTF-derived research peptide (Institute for Basic Research, New York) that crosses the blood-brain barrier and stimulates hippocampal neurogenesis in rodent models of Alzheimer disease, Down syndrome, and aging. Not FDA-approved; not commercially marketed; research-only with no human trials to date.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.